Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice

Respiratory Research

Volumn 8, Issue , 2007, Pages

  Paddenberg, Renate ^a   Stieger, Philipp ^a   von Lilien, Anna Laura ^a   Faulhammer, Petra ^a   Goldenberg, Anna ^a   Tillmanns, Harald H ^a   Kummer, Wolfgang ^a   Braun Dullaeus, Ruediger C ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ANIMAL; ANOXIA; ARTICLE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG; MALE; MOUSE; PATHOLOGY; VASCULARIZATION;

ANIMALS; ANOXIA; DISEASE MODELS, ANIMAL; FEMALE; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MALE; MICE; SIROLIMUS;

EID: 34248187453     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-8-15     Document Type: Article

References (34)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436. 10.1056/NEJMra040291, 15459304.
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997, 336:111-117. 10.1056/NEJM199701093360207, 8988890.
3. Wagenvoort CA. Vasoconstriction and medial hypertrophy in pulmonary hypertension. Circulation 1960, 22:535-546.
4. Kay JM, Kahana LM, Rihal C. Diffuse smooth muscle proliferation of the lungs with severe pulmonary hypertension. Hum Pathol 1996, 27:969-974. 10.1016/S0046-8177(96)90226-9, 8816894.
5. Wohrley JD, Frid MG, Moiseeva EP, Orton EC, Belknap JK, Stenmark KR. Hypoxia selectively induces proliferation in a specific subpopulation of smooth muscle cells in the bovine neonatal pulmonary arterial media. J Clin Invest 1995, 96:273-281. 185198, 7615796.
6. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811-2821. 1236676, 16200212, 10.1172/JCI24838.
7. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353:1412-1413. 10.1056/NEJMc051946, 16192491.
8. Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, von Der Leyen HE, Morris RE, Dzau VJ. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001, 21:1152-1158.
9. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323. 10.1056/NEJMoa035071, 14523139.
10. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005, 353:653-662. 10.1056/NEJMoa051175, 16105989.
11. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780. 10.1056/NEJMoa012843, 12050336.
12. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. Faseb J 2002, 16:771-780. 10.1096/fj.01-0658com, 12039858.
13. Gerasimovskaya EV, Tucker DA, Stenmark KR. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation. J Appl Physiol 2005, 98:722-731. 10.1152/japplphysiol.00715.2004, 15501927.
14. Quinlan TR, Li D, Laubach VE, Shesely EG, Zhou N, Johns RA. eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2000, 279:L641-L650.
15. Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA, Krymskaya VP. PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2002, 283:L354-L363.
16. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005, 115:2691-2694. 1236701, 16200204, 10.1172/JCI26593.
17. Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, Grimminger F. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 2004, 141:169-177.
18. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001, 104:424-428.
19. Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, Lafuma C, Harf A, Adnot S, Dortho MP. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 2001, 18:838-845. 10.1183/09031936.01.00084601, 11757635.
20. Weissmann N, Nollen M, Gerigk B, Ardeschir Ghofrani H, Schermuly RT, Gunther A, Quanz K, Fink L, Hanze J, Rose F, Seeger W, Grimminger F. Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. Am J Physiol Heart Circ Physiol 2003, 284:H931-H938.
21. Zhou L, Goldsmith AM, Bentley JK, Jia Y, Rodriguez ML, Abe MK, Fingar DC, Hershenson MB. 4E-binding protein phosphorylation and eukaryotic initiation factor-4E release are required for airway smooth muscle hypertrophy. Am J Respir Cell Mol Biol 2005, 33:195-202. 1578595, 15901615, 10.1165/rcmb.2004-0411OC.
22. Yamakawa T, Tanaka S, Kamei J, Kadonosono K, Okuda K. Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells. Eur J Pharmacol 2003, 478:39-46. 10.1016/j.ejphar.2003.08.044, 14555183.
23. Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M. Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Chest 2002, 122:326S-334S. 10.1378/chest.122.6_suppl.326S, 12475810.
24. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996, 98:2277-2283. 507677, 8941644.
25. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005, 111:926-931. 10.1161/01.CIR.0000155612.47040.17, 15710768.
26. Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2001, 163:498-502.
27. Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992, 22:307-325.
28. Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, Kourembanas S. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci U S A 2001, 98:8798-8803. 37515, 11447290, 10.1073/pnas.161272598.
29. Ito H, Adachi S, Tamamori M, Fujisaki H, Tanaka M, Lin M, Akimoto H, Marumo F, Hiroe M. Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: a possible endogenous endothelin-1-mediated mechanism. J Mol Cell Cardiol 1996, 28:1271-1277. 10.1006/jmcc.1996.0117, 8782068.
30. Proud CG. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004, 63:403-413. 10.1016/j.cardiores.2004.02.003, 15276465.
31. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ, Izumo S. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003, 107:1664-1670. 10.1161/01.CIR.0000057979.36322.88, 12668503.
32. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989, 341:755-757. 10.1038/341755a0, 2477714.
33. Ong AT, Serruys PW. Technology Insight: an overview of research in drug-eluting stents. Nat Clin Pract Cardiovasc Med 2005, 2:647-658. 10.1038/ncpcardio0378, 16306921.
34. Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G, Macdonald P, Esmore D, Muller D, Faddy S. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004, 110:2694-2700. 10.1161/01.CIR.0000136812.90177.94, 15262845.